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Following CD28/CD40 Blockade-Based Regimen1
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Megan M. Durham,* Thomas C. Pearson,* Rafi Ahmed,† and
Christian P. Larsen3*

I

n recent years, costimulation blockade therapies have played
a central role in strategies to induce mixed allogeneic chimerism and transplantation tolerance. Successful strategies
have included the use of preconditioning regimens consisting of
sublethal gamma-irradiation (1), as well as administration of large
numbers of donor bone marrow cells without preconditioning (2,
3). We have recently developed a model in which mice are preconditioned with a minimally myelosuppressive dose of the stem
cell-selective toxin busulfan, allowing for the engraftment of donor
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bone marrow under the cover of costimulation blockade. Skin grafts
given at the same time as bone marrow survive indefinitely (4).
A continuing concern in clinical transplantation is the effect tolerance induction regimens might have on immunity to pathogens.
One possible consequence is that in attempting to induce tolerance
to the allograft, antiviral immune responses could be compromised, leading to undesirable consequences for the transplant recipient. Conversely, ongoing viral infections could prove to be a
barrier to the successful induction of allograft tolerance. In support
of this latter scenario, it has recently been reported that acute infection with lymphocytic choriomeningitis virus (LCMV)4 Armstrong at the time of transplantation prevents tolerance induction
and induces rapid graft rejection (5, 6).
As preexisting chronic or latent infections are prevalent in transplant recipients (e.g., EBV, CMV, polyoma, hepatitis C), we
sought to apply a model of chronic viral infection. LCMV clone
13, in contrast to LCMV Armstrong, causes a long-term persistent
infection in mice that is cleared from serum over the course of 2–3
mo (7). In this study, we analyze the impact of an ongoing chronic
infection on the induction of tolerance. We also assess the ability
of recipient mice to maintain control of the infection following
costimulation blockade-based treatment. We find that the presence
of a chronic LCMV infection prevents the establishment of tolerance and deletion of donor-reactive T cells as long as 4 mo postinfection, long after viremia has been controlled. Moreover, analysis of the antiviral T cell response reveals that administration of
the tolerance regimen during persistent infection, and specifically
short-term costimulation blockade, results in sustained impairment
of responses to a panel of CD8 epitopes and a failure to control
viremia. To our knowledge, these data provide the first evidence
that persistent infections may prove to be a barrier to the clinical
application of costimulation blockade-based tolerance induction
regimens, and perhaps even more importantly that in the absence
of antiviral therapy, such regimens also have the potential to hamper protective antiviral immunity. Furthermore, we find that costimulation via the CD28 and CD40 pathways continues to be
essential for T cell responses to chronic infection well after initial
Ag exposure, expansion, and differentiation.
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A continuing concern with CD28 and/or CD40 blockade-based
strategies to induce tolerance and mixed chimerism is their
potential to disrupt protective immunity to preexisting infections. In this report, we find that preexisting persistent infection with lymphocytic choriomeningitis virus (LCMV) clone 13
prevents the induction of tolerance, mixed chimerism, and donor-reactive T cell deletion. Mice continue to be refractory to
tolerance induction even after viremia has been resolved and
virus is present only at very low levels in peripheral tissues.
Conversely, we find that the full tolerance regimen, or costimulation blockade alone, specifically inhibits already ongoing antiviral immune responses, leading to an inability to control
viremia. These findings suggest that ongoing T cell responses
continue to depend on costimulatory interactions in the setting
of a chronic infection and provide insight into potential risks
following costimulation blockade posed by chronic or latent
viral infections such as hepatitis C, EBV, and CMV. The
Journal of Immunology, 2002, 169: 5387–5391.
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Materials and Methods
Mice and virus infections
Adult male 6- to 8-wk-old BALB/c and C57BL/6 (B6) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). B6 LCMV carrier
mice were bred at Emory University (Atlanta, GA) as previously described
(8). Mice were infected with 2 ⫻ 105 PFU of LCMV Armstrong injected
i.p. to induce acute infection, or with 2 ⫻ 106 PFU of LCMV clone 13 (i.v.)
to induce chronic infection. Virus stocks were grown and quantitated as
previously described (7). Infectious LCMV in serum and tissues was measured by plaque assay on Vero cell monolayers as described (7).

Skin grafting
Full thickness skin grafts (⬃1 cm2) were transplanted on the dorsal thorax
of recipient mice and secured with a band-aid for 7 days. Graft survival was
then followed by daily visual inspection. Rejection was defined as the
complete loss of viable epidermal graft tissue.

Bone marrow preparation and treatment protocols

Cell preparations and flow cytometry
Intracellular IFN-␥ expression was induced in response to ex vivo restimulation with LCMV peptides as described (8). Cells were stained with antiIFN-␥ and anti-CD8 (BD PharMingen, San Diego, CA) using the Cytofix/
Cytoperm kit according to the manufacturer’s instructions (BD

FIGURE 1. Chronic infection with
LCMV clone 13 prevents tolerance induction and chimerism over a long time
course. B6 mice were infected with 2 ⫻
106 PFU of LCMV clone 13. At 15 (a–
c), 60 (d–f), or 120 (g–i) days postinfection, mice were treated with the tolerance
induction regimen and given a BALB/c
skin graft. j–l, LCMV immune mice also
received the tolerance regimen 30 days
after an acute infection with LCMV
Armstrong. a, d, g, Mice were bled on
days 15, 60, or 120 postinfection, respectively, and tested for the presence of
LCMV in the serum. The dotted line represents the limit of detection. Mice transplanted at these time points were assessed for skin graft survival (b, e, and h)
and donor cell chimerism (c, f, and i)
over a long time course (at day 15, n ⫽
15 for infected, n ⫽ 10 for uninfected; at
days 60 and 120, n ⫽ 9 for infected, n ⫽
8 for uninfected). Similar assays were
performed for LCMV-immune mice. j,
Serum titers were measured 30 days after
acute infection with LCMV Armstrong
(n ⫽ 5). Mice received the tolerance regimen and a BALB/c skin allograft ⬎30
days postinfection and were assessed for
skin graft survival (k) and chimerism (l)
(n ⫽ 10 for infected, n ⫽ 8 for uninfected). All error bars represent the SEM
(p ⬍ 0.001 for all infected vs uninfected
groups). Skin graft survival and chimerism data are pooled from two separate
experiments.

Results
Ongoing chronic infection, but not prior acute infection,
prevents tolerance induction, mixed chimerism, and deletion of
donor-reactive T cells
We have previously described a method for establishing indefinite
allospecific tolerance and 50 –70% mixed hemopoietic chimerism
following treatment with the stem cell-selective toxin busulfan,
administration of donor bone marrow, and blockade of the CD28
and CD40 costimulatory pathways (4). However, we have recently
reported that tolerance induction could be inhibited by a concurrent acute LCMV infection (6). In the present experiments, we
sought to determine the effects of preexisting long-term chronic
viral infections on tolerance induction, the development of hemopoietic chimerism, and the deletion of donor-reactive T cells. Mice
infected with LCMV clone 13 typically develop high viral titers in
the serum that are gradually controlled by the host T cell response
over the course of 2–3 mo. Virus is generally controlled and
cleared from the serum by day 90 postinfection and persists at very
low levels in peripheral organs indefinitely (7). We assessed the
efficacy of the tolerance regimen during the course of a chronic
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The mixed chimerism tolerance regimen, involving treatment with donor
bone marrow, busulfan (Busulfex; Orphan Medical, Minnetonka, MN),
CTLA4-Ig, and anti-CD40 ligand (CD40L) (MR1), has been described
elsewhere (4). The dose of MR1 (2 mg total over four treatments) has been
shown to generate therapeutically effective levels for ⬎50 days (9).

PharMingen). Peripheral blood was analyzed by staining with the indicated
fluorochrome-conjugated Abs (BD PharMingen), followed by RBC lysis
and washing with a whole blood lysis kit (R&D Systems, Minneapolis,
MN). Flow cytometry was performed on a FACSCalibur and data were
analyzed using CellQuest software (BD Biosciences, Braintree, MA).
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FIGURE 2. Chronic LCMV infection prevents deletion of donor-reactive T cells. B6 mice were infected with 2 ⫻ 106 PFU of LCMV clone 13, and
then received the tolerance regimen and a BALB/c skin graft 15 (a), 60 (b), or 120 (c) days postinfection. Mice were bled 120 days posttransplant and
peripheral leukocytes stained for the presence of V␤5⫹CD4⫹ and V␤11⫹CD4⫹ cells. The y-axis is the percentage of CD4⫹ cells that are also V␤5⫹ or
V␤11⫹ for infected (n ⫽ 5 for day 15, n ⫽ 4 for day 60, n ⫽ 4 for day 120), uninfected tolerant (n ⫽ 4 for all time points), B6 (n ⫽ 3), and BALB/c
(n ⫽ 3) mice. Error bars represent the SEM (p ⬍ 0.001 between all infected and uninfected tolerant groups).

mice with a prior acute LCMV Armstrong infection (⬎30 days
postinfection) accepted donor skin grafts (⬎200 days) indefinitely
and developed stable mixed chimerism (Fig. 1, k and l).
In aggregate, while 25 of 26 uninfected B6 mice were rendered
tolerant and chimeric, none of the 33 infected animals accepted
skin allografts or developed chimerism. It is notable that even mice
with no detectable virus in the serum rapidly rejected skin allografts following administration of donor bone marrow, busulfan,
and costimulation blockade.
To determine whether LCMV-induced skin graft rejection was
associated with impaired peripheral deletion of donor-reactive T
cells, we compared the use of V␤11 and V␤5.1/2 by CD4⫹ T cells
from B6 recipients in the uninfected group (accepted both bone
marrow and skin grafts) and from the infected groups (rejected
bone marrow and skin grafts). BALB/c mice delete V␤11- and
V␤5-bearing T cells in the thymus due to their high affinity for
endogenous retroviral superantigens (mouse mammary tumor virus) presented by I-E MHC class II molecules, whereas B6 mice do
not express I-E and thus use V␤11 on ⬃5–7% of CD4⫹ T cells and
V␤5.1/2 on ⬃3–5% of CD4⫹ T cells. Treatment with costimulation blockade and the subsequent development of chimerism in B6
recipients results in the deletion of the donor-reactive V␤5 and
V␤11 subsets (2, 3). Mice receiving the tolerance regimen 15, 60,

FIGURE 3. Costimulation blockade-based therapies prevent control of ongoing chronic infection. a, B6 mice were infected with LCMV clone 13 and
received either no further treatment (No Tx; n ⫽ 7) or the tolerance regimen on days 15 (d15 Tx; n ⫽ 8, p ⬍ 0.01 vs No Tx), 60 (d60 Tx; n ⫽ 8, p ⬍
0.05 vs No Tx), or 120 (d120 Tx; n ⫽ 6) postinfection. Mice were bled at day 150 postinfection and serum was tested for the presence of LCMV. The
y-axis displays plaque forming units per milliliter. The dotted line indicates the limit of detection for this assay. b, B6 mice were treated with LCMV and
received either no further treatment (No Tx; n ⫽ 10) or administration of CTLA4-Ig and anti-CD40L starting on day 0 (CB day 0; n ⫽ 10, p ⬍ 0.05 vs
No Tx) or day 20 (CB day 20; n ⫽ 10, p ⬍ 0.05 vs No Tx) postinfection. Mice were bled on day 90 postinfection and serum was tested for the presence
of LCMV. The y-axis displays plaque forming units per milliliter in the serum. The dotted line indicates the limit of detection for this assay. Results are
pooled from two separate experiments.
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infection by administering the tolerance induction protocol to mice
15, 60, and 120 days postinfection. As expected, viral titers in mice
infected with LCMV clone 13 gradually decrease and disappear
from the serum by day 120 postinfection (Fig. 1, a, d, and g).
However, low levels of virus persisted in the kidneys of infected
mice as late as 250 days postinfection (data not shown). Conversely, mice infected with LCMV Armstrong, an acutely infecting strain, rapidly clear the virus from the serum (Fig. 1j) and
peripheral tissues (data not shown).
B6 mice receiving a BALB/c skin graft along with donor bone
marrow, costimulation blockade, and busulfan 15 days postinfection rejected their grafts promptly (Fig. 1b, median survival time
(MST) ⫽ 18 days). In contrast, 10 of 10 uninfected control mice
displayed indefinite graft survival (MST ⬎200 days). Infected
mice also failed to develop detectable levels of stable mixed chimerism, while uninfected controls generally developed ⱖ50% chimerism in the peripheral blood by day 60 (Fig. 1c). Mice also
rejected skin grafts promptly when receiving the tolerance regimen
60 (MST ⫽ 23 days) or 120 (MST ⫽ 27 days) days postinfection
(Fig. 1, e and h). Failure to accept skin grafts was further reflected
in a failure to generate mixed chimerism following transplantation
of infected mice, while uninfected controls established high levels
of stable mixed chimerism (Fig. 1, f and i). In comparison, 8 of 10
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or 120 days postinfection were bled 120 days posttransplant and
tested for the presence of V␤5- and V␤11-bearing CD4⫹ T cells.
Chronic infection with LCMV prevented the deletion of donorreactive T cells at all time points (Fig. 2). In contrast, tolerant
control animals deleted these subsets. We concluded that inhibition
of tolerance induction by chronic LCMV infection was associated
with a failure to delete donor-reactive T cells from the periphery.
Costimulation blockade impairs ongoing antiviral immunity

FIGURE 4. Costimulation blockade blunts ongoing antiviral CD8 T cell
responses. B6 mice were infected with LCMV clone 13. At 20 days postinfection, they either received no further treatment (No Tx; n ⫽ 3), the
tolerance regimen (Tol. reg.; n ⫽ 5), or costimulation blockade alone (CB;
n ⫽ 4). Fifteen days later, splenocytes were harvested, restimulated with
the indicated peptides in the presence of brefeldin A, and stained for intracellular expression of IFN-␥. Splenocytes were restimulated with the
gp33– 41, nuclear protein 396 – 404, gp276 –286, or gp118 –128 peptides,
as indicated on the x-axis. The total number of CD8⫹IFN-␥⫹ cells per
spleen of each treatment group is indicated on the y-axis, as calculated
based on the percentage of CD8⫹IFN-␥⫹ and the total number of splenocytes harvested. Error bars represent the SEM (p ⬍ 0.001 for uninfected
group vs either infected group for gp33– 41, gp276 –286, and gp118 –128).

the induction of tolerance in a variety of costimulation blockadebased models (5, 6, 11), it seems likely that chronic LCMV infection will also disrupt other CD28/CD40 blockade-based tolerance
induction regimens.
Although CD28 and CD40 have been found to be largely dispensable for clearance of an acute LCMV infection (12–14), T cell
costimulatory pathways are much more important for dealing with
more potent persistent infections (12). Our report indicates that
Ag-specific CD8 T cells continue to require CD28/CD40 costimulation in the setting of chronic infection even well after priming,
activation, and expansion (as late as 60 days into the response), as
demonstrated by our observation that ongoing CD8 responses are
down-modulated following costimulatory blockade. Interestingly,
blockade of costimulatory pathways has been shown to be effective
in preventing the onset of autoimmunity in mouse models (15, 16).
Our data provide a rationale for such treatment in ameliorating
ongoing disease (17).
Latent or persistent viral infections are very common in adult
human transplant recipients, and loss of immune control of these
viruses following transplantation results in significant morbidity
and mortality. It is crucial to understand the effects of tolerance
regimens on other chronic persistent or latent infections, such as
hepatitis C, polyoma, EBV, and CMV. Further studies should further dissect the pathways whereby chronic LCMV promotes the
generation of CD28/CD40-independent alloresponses and eventual
graft rejection.

Discussion
In this report, we demonstrate that chronic LCMV infection, but
not prior acute infection, prevents the induction of chimerism and
donor-specific tolerance and predisposes toward the CD28/CD40independent rejection of skin allografts. Remarkably, even mice
receiving transplants as long as 120 days postinfection were resistant to the effects of the tolerance regimen, despite the fact that
viremia had been resolved and virus persisted only at very low
levels in peripheral tissues such as the kidney. Graft rejection correlated with a failure to delete donor-reactive T cells. Given that
concurrent infection with acute LCMV has been shown to prevent
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